Overall, our cell line data strongly support the notion that resistance to treatment and particularly to olaparib in BRCA1-deficient cancer cells is frequently associated with restoration of RAD51 foci formation, thus, signing for restored HR capacity. The gene discussed is RAD51; the disease is cancer.